ASC Partners with Tokyo Medical and Dental University (TMDU) to Expand TARGATT™ Site-Specific Gene Integration Technology for Engineering Advanced Transgenic Mouse Models | ASC


12/11/17 MILPITAS, Calif.--Applied StemCell, Inc. (ASC), a leading biotechnology company providing genome editing services to the biomedical research community worldwide, is very proud to announce its partnership with the Department of Experimental Animal Model for Human Disease, Tokyo Medical and Dental University (TMDU), Japan. This partnership will focus on improving and expanding the efficiency of ASC’s site-specific gene integration technology, TARGATT™, to generate humanized mouse models, gene knock-down, inducible gene expression, tissue-specific Cre expression mouse models and more.

The Department of Experimental Animal Model for Human Disease (TMDU), an affiliated laboratory of the Center for Experimental Animals is one of the largest and leading laboratory animal facilities in Japan. The center employs the most advanced and promising technologies to develop novel mouse models to help elucidate the molecular mechanisms underlying human diseases, specifically congenital abnormalities and fertility disorders, and to foster efficient prenatal diagnosis for genetic disorders in early embryos.

In a statement by ASC’s Chief Scientific Officer and co-founder, Dr. Ruby Yanru Chen-Tsai stated, “I have admired Dr. Kanai’s research and accomplishments for many years, and am excited to collaborate with her and her team at the Center for Experimental Animals, TMDU, to expand ASC’s TARGATT™ technology and its applications. We look forward to developing better physiologically relevant mouse and other animal models using this technology”.

The TARGATT™ technology was co-developed by Dr. Chen-Tsai and Dr. Liqun Luo of Stanford University and utilizes the φC31 phage integrase system for site-specific integration of transgenes into a preselected locus in the genome. The TARGATT™ technology overcomes drawbacks of random integration, and is adaptable for gene integration in many different species of animals (mice, rats, rabbits, pigs) and cell lines (including stem cells and immortalized cell lines).

“We eagerly look forward to this collaboration with Applied StemCell, to use its TARGATT™ technology for improving our transgenic mouse model generation platform, for the purpose of developing advanced and humanized mouse models”, said Professor Masami Kanai-Azuma, Director of the Center for Experimental Animals at TMDU.

This partnership follows Applied StemCell’s ISO:9001 and 13485 certifications for high quality services and products. Upgrades to the TARGATT™ technology will help provide superior animals models for biomedical research with better representation of human physiology and genetics.

ASC’s Strategy and Pipeline

ASC’s strategy is to utilize its core strengths to expand its IP portfolio and develop a strong therapeutic pipeline based on its patented gene editing technologies. The company’s expertise in utilizing genome editing for both animal and cell model generation, as well as its portfolio of improved genome editing technologies, make it uniquely poised to develop transformative solutions to pressing medical challenges.

About Applied StemCell

Applied StemCell, Inc. is a leading stem cell and gene-editing company focused on the development of products and therapeutics that are enabled by its proprietary gene editing platform technologies TARGATT™ and CRISPR/Cas9. For more information, please visit www.appliedstemcell.com.

 

Contact:

Maki Ogawa

Marketing Director, Applied StemCell, Inc.

408-773-8007

maki.ogawa@appliedstemcell.com

Google